Supplemental material for "Tildrakizumab efficacy, drug survival, and safety are comparable in patients with psoriasis with and without metabolic syndrome: Long-term results from two phase 3 randomized controlled studies (reSURFACE 1 and reSURFACE 2)"
收藏NIAID Data Ecosystem2026-03-12 收录
官方服务：
资源简介：
Supplemental material for Lebwohl, et al., "Tildrakizumab efficacy, drug survival, and safety are comparable in patients with psoriasis with and without metabolic syndrome: Long-term results from two phase 3 randomized controlled studies (reSURFACE 1 and reSURFACE 2)," J Am Acad Dermatol, 2020
创建时间：
2020-09-16
